Dr. Reddy's Laboratories faces a deteriorating fundamental picture with declining revenue of 12% year-over-year, two consecutive earnings misses, a death cross blocking entry, and the stock already priced above analyst targets — making the current setup one of the weakest risk-reward profiles in the healthcare sector despite reasonable absolute valuation multiples.
Thesis pillars
- Revenue Decline And Miss Pattern→Stable
- Death Cross And Negative Asymmetry→Stable
- Extreme Put Call Ratio↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Dr. Reddy's Laboratories Ltd (RDY) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $14.77 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and... Read more
Sell if holding. Analyst target reached at $14.77 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: Death cross but MACD improving, RSI 92. Score 4.8/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 23, 2026Recent Developments — Dr. Reddy's Laboratories Ltd
Latest news
- NEWS Dr. Reddy's Laboratories (RDY) Reports Q2 Earnings; Shares Trade Below GF Value™ - GuruFocus — GuruFocus Oct 23, 2026 neutral
- NEWS Dr. Reddy's Laboratories Q2 Earnings Call Highlights - Yahoo Finance — Yahoo Finance Oct 23, 2026 neutral
- NEWS Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 Earnings - Quiver Quantitative — Quiver Quantitative Oct 23, 2026 negative
- NEWS Dr. Reddy's Laboratories (NYSE:RDY) Stock Rating Raised to "Hold" at Wall Street Zen - MarketBeat — MarketBeat Oct 17, 2026 positive
- NEWS Dr. Reddy's Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat — MarketBeat Oct 15, 2026 neutral
Latest item Oct 23, 2026 · Generated 2026-11-05T11:59:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -1.5% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $14.77 — A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: Death cross but MACD improving, RSI 92. Prior stop was $14.19. Score 4.8/10, moderate confidence.
Analyst target $12.52 reached (−15.3% from $14.77); no take-profit level is published. Prior stop was $14.19. Stop-loss: $14.19.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Consecutive earnings misses (2).
Dr. Reddy's Laboratories Ltd trades at a P/E of 41.0 (forward 22.3). TrendMatrix value score: 5.7/10. Verdict: Sell.
42 analysts rate RDY, with a consensus score of 3.7/5. 5 analysts publish price targets averaging $14.
What does Dr. Reddy's Laboratories Ltd do?Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company...
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.